688799 Hunan Warrant Pharmaceutical
- 46.47
- -0.33-0.71%
Hunan Warrant Pharmaceutical News
Warner Pharma (688799.SH): The application for listing of ipratropium bromide has been approved.
Warner Pharmaceutical Co., Ltd. (688799.SH) released an announcement that its wholly-owned subsidiary, Hunan Warner Chiral Medicine Co., Ltd.,...
Express News | Hunan Warrant Pharmaceutical Says It Aims to Raise up to 500 Mln Yuan in Share Private Placement to Replenish Capital
Hunan Warrant Pharmaceutical Co.,Ltd's (SHSE:688799) Price Is Right But Growth Is Lacking
When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 31x, you may consider Hunan Warrant Pharmaceutical Co.,Ltd (SHSE:688799) as an attractive investment with its
Warner Pharmaceuticals (688799.SH): Subsidiary drug arginine ibuprofen obtained approval notice for marketing application
Gelonghui, May 29丨Warner Pharmaceuticals (688799.SH) announced that recently, Hunan Warner Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Chemical Ingredient Marketing Application Approval Notice” (Notice No.: 2024YS00463) of arginine ibuprofen issued by the State Drug Administration and publicized it on the China Drug Administration Drug Evaluation Center (CDE) “Registration Information Disclosure of Active Pharmaceutical Ingredients, Pharmaceutical Excipients and Pharmaceutical Packaging Materials” platform. Arginine ibuprofen is an anti-inflammatory analgesic. It is mainly suitable for the following symptoms: toothache, dysmenorrhea, pain due to trauma (for example: movement
Warrant Pharmaceutical's Unit Gets Nod to Market Benidipine Hydrochloride
Hunan Warrant Pharmaceutical's (SHA:688799) unit, Hunan Warrant Pharmaceutical Chiral Drug, received approval from China's National Medical Products Administration to market raw drug ingredient benidi
Warner Pharmaceuticals (688799.SH): Benidipine hydrochloride API received approval notice for marketing application
Gelonghui, May 27丨Warner Pharmaceuticals (688799.SH) announced that its wholly-owned subsidiary Hunan Warner Pharmaceutical Co., Ltd. received the “Notice of Approval of the Marketing Application for Chemical Ingredients” of benidipine hydrochloride issued by the State Drug Administration and publicized it on the “Registration Information Disclosure of Active Pharmaceutical Ingredients, Pharmaceutical Excipients and Pharmaceutical Packaging Materials” platform of the China Drug Administration (CDE) Drug Evaluation Center (CDE). Benidipine hydrochloride is a calcium channel blocker, mainly used to treat essential hypertension and angina pectoris. Benidipine hydrochloride is combined with DHP binding sites in cell membrane voltage-dependent calcium channels to inhibit calcium ions
Warner Pharmaceuticals (688799.SH) plans to explore investment opportunities in the medical and health sector in markets such as China and Southeast Asia through funds
Warner Pharmaceuticals (688799.SH) announced that the company plans to invest no more than RMB 40 million to pledge Hainan Heyi...
Warner Pharmaceuticals (688799.SH): Plans to exceed 100 million yuan to participate in the establishment of Queshan Huazi
Gelonghui, April 19丨Warner Pharmaceuticals (688799.SH) announced that in order to keep up with the trend and trend of macromolecular innovative drugs becoming mainstream drug use around the world, use the investment experience and resources of professional investment institutions to explore investment opportunities in innovative application fields related to the pharmaceutical industry, strengthen the company's capabilities in macromolecular drug research and development, and actively use external talents and capital to complete the company's new drug R&D transformation and product upgrade strategy with efficiency and low risk. The company now plans to work as a limited partner, Beijing Qushan Investment Management Co., Ltd., Hunan Jinyang Investment Group The limited company and other partners signed the “”
Warner Pharmaceuticals (688799.SH): Plans to build a “Green Intelligent Manufacturing Base (Phase I) with an annual output of 3,000 tons of high-end APIs and intermediates for no more than 650 million yuan
Gelonghui, April 19 | Warner Pharmaceuticals (688799.SH) announced that based on the strategic development plan, the company plans to invest no more than 650 million yuan to build the “Green Intelligent Manufacturing Base (Phase I) Construction Project with an annual output of 3,000 tons of high-end APIs and intermediates” through Zhigen Pharmaceutical's investment of no more than 650 million yuan. After the construction of the project is completed, it will further expand the production scale of the company's high-end APIs and intermediates, enhance the company's green and intelligent manufacturing capabilities, consolidate the company's ability to integrate raw materials and formulations, lay the foundation for the domestic and international industrialization layout of the company's high-end APIs and intermediate products, and enhance the company's industrial support and profitability
Warner Pharmaceuticals (688799.SH): Net profit of 60.5531 million yuan in the first quarter increased 21.90% year-on-year
Gelonghui, April 19: Warner Pharmaceuticals (688799.SH) released its report for the first quarter of 2024. Operating revenue for the reporting period was 373 million yuan, up 4.38% year on year; net profit attributable to shareholders of listed companies was 60.5531 million yuan, up 21.90% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 44.2789 million yuan, up 0.28% year on year; basic earnings per share were 0.64 yuan.
Approval for Warner Pharmaceuticals (688799.SH) to issue convertible corporate bonds to unspecified targets expires
Warner Pharmaceuticals (688799.SH) announced that the company is obtaining approval to issue convertible corporate bonds to unspecified targets...
Private Companies Are Hunan Warrant Pharmaceutical Co.,Ltd's (SHSE:688799) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥427m Last Week
Key Insights Significant control over Hunan Warrant PharmaceuticalLtd by private companies implies that the general public has more power to influence management and governance-related decisions 56%
Hunan Warrant Pharmaceutical Co.,Ltd's (SHSE:688799) Shares Bounce 43% But Its Business Still Trails The Market
Hunan Warrant Pharmaceutical Co.,Ltd (SHSE:688799) shareholders would be excited to see that the share price has had a great month, posting a 43% gain and recovering from prior weakness. Taking a w
If EPS Growth Is Important To You, Hunan Warrant PharmaceuticalLtd (SHSE:688799) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. But the reality is that when a company lose
Warner Pharmaceuticals (688799.SH): The company's docusate sodium tablets are an exclusive domestic formulation
Gelonghui, January 29丨Warner Pharmaceuticals (688799.SH) recently said during a survey reception from institutional investors that the company's docusate sodium tablets are an exclusive domestic formulation. Docurate sodium is an anionic surfactant. After oral administration, it promotes water and fatty substances to soak into feces and physically lubricates intestinal defecation, and is used for chronic functional constipation. Docusate sodium tablets are not equivalent to laxatives. They have mild effects and are highly safe.
Warner Pharmaceuticals (688799.SH): Currently, the company has won the bid for 4 varieties, including montmorillonite powder and polyethylene glycol 4,000 powder, for national collection
Gelonghui, January 29丨Warner Pharmaceuticals (688799.SH) recently said during a survey receiving institutional investors that at present, the company's 4 varieties, including montmorillonite powder, polyethylene glycol 4000 dispersion, matimecoferyl ester capsules, and levosalbutamol hydrochloride atomized inhalation solution, have won the bid for continued procurement after the expiration of national collection agreements in various regions; acetylcysteine solution for inhalation, lansoprazole enteric tablets, and calcium carbonate 3 D3 tablets for children Tablets, metformin glipizide tablets, nifedipine sustained-release tablets, colloidal pectin bismuth capsules, etc. The variety also won the bid in some places
Warner Pharmaceuticals (688799.SH): Continued investment in R&D in the fields of innovative drugs, improved new drugs, and generic drugs
GLONGHUI, January 29丨Warner Pharmaceuticals (688799.SH) recently said during a survey receiving institutional investors that in terms of formulations, the company will continue to invest in R&D in the fields of innovative drugs, improved new drugs, generic drugs, etc., to ensure a continuous increase in the number of new product registrations and bring new revenue growth points to the company. In the future, new products will be approved one after another, which will guarantee the steady growth of the company's performance. At the same time, the company will actively promote the participation of pharmaceutical products in national procurement and regional alliance procurement, make full use of the cost advantages of integrating APIs and formulations, and further increase the sales scale of the company's pharmaceutical products. In terms of APIs, the company also
Warner Pharmaceuticals (688799.SH): Compound polyethylene glycol electrolyte dispersion (III) obtained drug registration certificate
Gelonghui, January 29丨Warner Pharmaceuticals (688799.SH) announced that the company received the Compound Polyethylene Glycol Electrolyte Powder (III) “Drug Registration Certificate” approved and issued by the State Drug Administration. Compound polyethylene glycol electrolyte dispersion (III) is used to prepare patients for colon cleansing before the following conditions: endoscopic or radiological examinations; colon surgery. This product is suitable for adults. The polymer polyethylene glycol (4000) is a long-chain polymer, and water molecules bind to it through hydrogen bonds. After oral administration of this medicine, the volume of fluid in the intestines increases. These unabsorbed intestinal fluids give this medicine laxative properties.
Warner Pharmaceuticals (688799.SH): Currently, the company has 57 specialty chemical raw materials
Gelonghui, January 26丨Warner Pharmaceuticals (688799.SH) recently said during a survey by institutional investors that at present, the company has 57 specialty chemical ingredients, and 41 of these products have a “A” registration number status. The company focuses on building an “API marketing platform combining related services and strategic customization” to promote links between the company's APIs and domestic generic drug companies and further expand the market share of the company's superior raw materials. At the same time, it is actively developing international registration and linking of API products to promote the export of the company's API products. In 2022, the company's raw materials and intermediates and other products
Warner Pharmaceuticals (688799.SH): The ZY022 project has now completed pre-clinical research
Gelonghui, January 26 | Warner Pharmaceuticals (688799.SH) recently said during a survey receiving institutional investors that the company's shareholding company, Hunan Tianji Rare Chinese Herbal Medicine Development Co., Ltd. and the Pharmaceutical Research Institute of the Chinese Academy of Medical Sciences, have jointly carried out research projects on artificial substitutes for rare and endangered animal medicinal materials, and have signed a number of cooperative research agreements on artificial substitutes for rare and endangered animal medicinal materials. Using its own mature production support systems such as biological fermentation, chemical synthesis, extraction of traditional Chinese medicine, and separation and purification of monomer components, the company is entrusted with completing pilot testing, production verification, and subsequent research related to these projects.
Analysis
Price Target
No Data
